University of Western Ontario

GFAP Biomarker Analysis Shows Ozanimod's Impact on MS Disease Progression in ENLIGHTEN Trial

- Interim analysis of ENLIGHTEN trial reveals ozanimod treatment reduced mean GFAP concentration from 115.0 to 103.2 pg/mL over one year in relapsing multiple sclerosis patients. - GFAP levels showed significant correlations with various MRI parameters, including positive associations with lesion volumes and negative correlations with brain volume measures. - Patients demonstrated cognitive improvements with ozanimod treatment, with 48.1% achieving clinically meaningful improvement in SDMT scores after one year.